China's NMPA approves AUGTYRO™ (repotrectinib) by Zai Lab for ROS1-positive NSCLC, based on the TRIDENT-1 study.

Zai Lab announces China's NMPA approval of AUGTYRO™ (repotrectinib) for treating ROS1-positive NSCLC. The approval is based on the TRIDENT-1 study, which evaluated repotrectinib in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC. Zai Lab's President, Rafael G. Amado, highlights the significant unmet need for these patients due to the limited durability of benefit with existing therapies.

May 13, 2024
4 Articles

Further Reading